Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Open-Label Study to Explore Tissue Histopathology Following Subcutaneous Injection of Collagenase Clostridium Histolyticum Using An Abdominoplasty Model

NCT04236635 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT04236635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04236635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Open-Label Study to Explore Tissue Histopathology Following Subcutaneous Injection of Collagenase Clostridium Histolyticum Using An Abdominoplasty Model
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 2
Overall status
Completed
Start date
December 20, 2019
Completion date
October 26, 2020
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

characteristics of subcutaneous tissue